TheraSorb™ Therapeutic Apheresis is based on the selective removal of pathogenic substances, i.e. substances, that cause diseases, from the patient’s plasma (liquid part of the blood).
Apheresis, from the Greek word “to take away” describes the process in which the blood is processed through an apparatus that separates out a particular constituent and returns the remainder to the patient

During Apheresis, target molecules are selectively removed while the plasma is re-infused into the patient. Hence, larger volumes of plasma can be processed that in therapeutic plasma exchange. Since no substitution fluid is required, the treatment is usually very well tolerated.
Different adsorbers in the TheraSorb product line can be used to selectively remove either undesired immunoglobulins (antibodies), Low Density Lipoprotein (LDL, “bad cholesterol”) and Lipoprotein(a) (Lp (a)) or the plasma proteins fibrinogen and C-reactive protein (CRP).

Treatment procedure

Independent of the adsorber used, blood is drawn from the patient’s vein and directed to the “Disk Separator”. The Disk Separator is a device that separates plasma and the cellular components of the blood. The plasma is then directed into the adsorber. The various adsorbers contain a specific matrix that selectively retain the respective undesired substances. After passing through the absorber’s matrix, the plasma is recombined with the cellular components and returned to the patient

TheraSorb™ Therapeutic Apheresis components

A TheraSorb™ Therapeutic Apheresis treatment is performed with

  • The Life 18 Apheresis unit: a device for the extracorporeal plasma treatment
  • A pair of TheraSorb adsorbers: for the selective removal of pathogenic substances
  • The Life 18 Theraline tubing set TheraSorb regeneration and storage solutions

This system sets benchmarks for safety, user-friendliness, and flexibility in the treatment of various diseases. The hardware and software concept of the LIFE 18 Apheresis Unit, combined with multiple light and pressure sensors, ensures the safe treatment of the patient. The modular concept permits flexible treatment schemes as well as adaptivity for novel applications currently under development


  LIFE 18
  LDL Adsorbers
  Ig Adsorbers
  Rheo Adsorbers
  Therapeutic Plasma Exchange